Arcadia Biosciences, Inc.
RKDA
$3.25
$0.26548.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.22M | 1.54M | 1.31M | 1.26M | 777.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.22M | 1.54M | 1.31M | 1.26M | 777.00K |
| Cost of Revenue | 643.00K | 1.05M | 643.00K | 1.09M | -36.00K |
| Gross Profit | 573.00K | 484.00K | 663.00K | 163.00K | 813.00K |
| SG&A Expenses | 2.65M | 2.24M | 2.68M | 3.19M | 1.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.34M | 3.30M | 3.33M | 4.28M | 1.72M |
| Operating Income | -2.13M | -1.76M | -2.02M | -3.03M | -940.00K |
| Income Before Tax | -4.03M | -1.18M | 1.85M | -2.42M | -445.00K |
| Income Tax Expenses | 8.00K | -- | -- | -- | 7.00K |
| Earnings from Continuing Operations | -4.04M | -1.18M | 1.85M | -2.42M | -452.00K |
| Earnings from Discontinued Operations | -27.00K | -430.00K | -789.00K | -- | -2.40M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 0.00 |
| Net Income | -4.06M | -1.61M | 1.06M | -2.42M | -2.85M |
| EBIT | -2.13M | -1.76M | -2.02M | -3.03M | -940.00K |
| EBITDA | -2.10M | -1.75M | -1.99M | -2.98M | -880.00K |
| EPS Basic | -2.98 | -1.18 | 0.78 | -1.78 | -2.10 |
| Normalized Basic EPS | -1.77 | -0.54 | -0.99 | -1.09 | -0.09 |
| EPS Diluted | -2.98 | -1.18 | 0.78 | -1.78 | -2.10 |
| Normalized Diluted EPS | -1.77 | -0.54 | -0.99 | -1.09 | -0.09 |
| Average Basic Shares Outstanding | 1.37M | 1.36M | 1.36M | 1.36M | 1.36M |
| Average Diluted Shares Outstanding | 1.37M | 1.36M | 1.36M | 1.36M | 1.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |